Drug Patent Watch
OCTOBER 28, 2024
The pharmaceutical industry relies heavily on Contract Development and Manufacturing Organizations (CDMOs) to streamline the drug development and manufacturing process. CDMOs provide a wide range of services that cater to the diverse needs of pharmaceutical companies, from early-stage development to commercial manufacturing.
Bio Pharma Dive
OCTOBER 28, 2024
Assure the integrity and efficiency of your clinical trials with support from a Biospecimen Manager.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 28, 2024
The Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) 2024 is a strategic platform for discussion and collaboration among decision makers, researchers and technologists who understand and follow this tendency.
Bio Pharma Dive
OCTOBER 28, 2024
Novartis follows cross-town rival Roche in partnering with Monte Rosa Therapeutics on so-called molecular glue degraders that can target “undruggable” proteins.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
OCTOBER 28, 2024
The enduring effects of redlining on public health, particularly on asthma prevalence, provide a striking example of how discriminatory housing policies from the 20th century continue to shape the well-being of marginalised communities affected by this practice today.
Bio Pharma Dive
OCTOBER 28, 2024
Learn why print remains a preferred channel for healthcare communications, and how printed materials can help build relationships with patients, develop brand loyalty and maintain brand consistency.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
OCTOBER 28, 2024
Buying Aliada Therapeutics would hand AbbVie a clinical-stage Alzheimer’s medicine and a drugmaking technology that may be useful for a variety of brain diseases.
Pharmaceutical Technology
OCTOBER 28, 2024
Motivated patients with rare diseases are using social media widely, making it an effective way to reach patients for trial recruitment.
Bio Pharma Dive
OCTOBER 28, 2024
With the new clinical trial diversity guidelines, the combination of EHR data and AI will be essential.
Pharmaceutical Technology
OCTOBER 28, 2024
Ahead of the upcoming DSCSA November deadline, pharma companies reimagine track-and-trace to tackle the US counterfeit drug landscape.
Rethinking Clinical Trials
OCTOBER 28, 2024
Research-identifiable Medicare data can come from traditional fee-for-service Medicare claims or from Medicare Advantage claims. A new contribution to the Living Textbook of Pragmatic Clinical Trials published this month, Use of Medicare Data in PCTs , describes the important differences between these data. At the healthcare system level, differences in incentives for documenting diagnoses can affect the reliability and relevance of data used for pragmatic clinical trials.
Pharmaceutical Technology
OCTOBER 28, 2024
China's virtual monopoly on the supply of many APIs could be dangerous for the security of medicine supply to Western countries.
Fierce Pharma
OCTOBER 28, 2024
Novartis and Apellis Pharmaceuticals have rolled out detailed data on iptacopan and pegcetacoplan, respectively, as they race for the prize in a type of rare kidney disease. | Novartis and Apellis dropped new data on their respective meds, iptacopan and pegcetacoplan, in the rare kidney disease C3 glomerulopathy. While Apellis' drug seems to have an efficacy edge based on a cross-trial comparison, Novartis may have gotten the jump by filing for approvals ahead of its competitor.
Pharmaceutical Technology
OCTOBER 28, 2024
As the retail drug pharmacy space undergoes significant change, new formats and designs that centre on the consumer are emerging.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
OCTOBER 28, 2024
In a recent pharmaphorum webinar, we sat down with Melanie Walsh, Senior Director, IBD Franchise Customer Experience and Digital Innovation, at Takeda, to learn some tips for successful content transformation.
Pharmaceutical Technology
OCTOBER 28, 2024
The US FDA has approved Iterum Therapeutics' NDA for ORLYNVAH to treat uncomplicated urinary tract infections (uUTIs).
pharmaphorum
OCTOBER 28, 2024
Novartis says Fabhalta shows sustained efficacy in rare disease C3G over 12 months, as it prepares for an FDA filing later this year
Pharmaceutical Technology
OCTOBER 28, 2024
Astellas has announced the withdrawal of its MAA for ACP from the EMA to treat geographic atrophy (GA) secondary to AMD.
XTalks
OCTOBER 28, 2024
November is National Diabetes Month. This year’s theme of National Diabetes Month 2024, “Take Charge of Tomorrow: Preventing Diabetes Health Problems,” highlights how today’s actions can shape healthier futures. On National Diabetes Month 2024, healthcare organizations, policymakers and community programs are raising awareness for the nearly 29.3 million Americans with diagnosed diabetes, alongside 9.7 million undiagnosed and 115.9 million at risk with prediabetes, based on the Ameri
Pharmaceutical Technology
OCTOBER 28, 2024
UPFs have become a staple of many diets worldwide, but overconsumption is contributing to an obesity epidemic in India.
pharmaphorum
OCTOBER 28, 2024
Apple wins in patent infringement lawsuit with wearable maker Masimo, but fails to get the injunction on sales that it sought
Pharmaceutical Technology
OCTOBER 28, 2024
The US FDA has granted orphan drug designation (ODD) to Modalis Therapeutics’ MDL-101, aimed at treating LAMA2-CMD.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Fierce Pharma
OCTOBER 28, 2024
Earlier this year, EyePoint Pharmaceuticals’ drug-device combo Duravyu missed the mark in a non-proliferative diabetic retinopathy (NPDR) study, raising doubts about the product’s potential in seve | EyePoint released new diabetic macular edema data Monday that a Mizuho Securities analyst described as "very promising." The trial win provides a needed turnaround for the company's lead candidate Duravyu, which failed a study in non-proliferative diabetic retinopathy earlier this yea
pharmaphorum
OCTOBER 28, 2024
Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class therapies for the disorder.Data reported at the Kidney Week 2024 congress in San Diego showed that felzartamab was able to achieve "substantial" reductions in proteinuria and stabilised kidney function in the 54-subject IGNAZ study that extended for 18 months after the last dose of the antibody.
Fierce Pharma
OCTOBER 28, 2024
While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA) in the United States, both companies are struggling to reach patients in the indication in Europe.&nb | While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA) in the United States, both companies are struggling to reach patients in the indication in Europe.
pharmaphorum
OCTOBER 28, 2024
MSD and Moderna start a third phase 3 trial of their V940 cancer vaccine, their second in early-stage lung cancer.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
BioPharma Reporter
OCTOBER 28, 2024
Vicky Marriottâs journey from enjoying school math to heading a global team of statisticians at Phastar reveals her belief in the power of empathy and collaboration.
pharmaphorum
OCTOBER 28, 2024
Discover the latest advancements in cell therapy with the next generation of innovative treatments that are revolutionising healthcare. Explore the future of medicine today.
Pharmaceutical Commerce
OCTOBER 28, 2024
Albert Thigpen, co-founder, Talentwise Consulting, explains how to use these tactics in order to anticipate the future US healthcare policy environment.
pharmaphorum
OCTOBER 28, 2024
Astellas confirmed today it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy in the EU
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
78 
Let's personalize your content